OcuMet Beacon for Age-Related Macular Degeneration
(FPF in AMD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is:* to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophyParticipants will undergo FPF imaging using the OcuMet Beacon system.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the OcuMet Beacon treatment different from other treatments for age-related macular degeneration?
What data supports the effectiveness of the treatment FPF Imaging, Flavoprotein Fluorescence Imaging, OcuMet Beacon System for age-related macular degeneration?
Who Is on the Research Team?
Mihai Mititelu, MD, MPH
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
This trial is for individuals with Age-Related Macular Degeneration (AMD), a condition affecting the retina. It's designed to see if stressed cells in the retina show up in specific imaging before symptoms appear or the disease progresses.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo FPF imaging using the OcuMet Beacon system and FAF imaging using Heidelberg Spectralis
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- FPF Imaging
FPF Imaging is already approved in United States, European Union for the following indications:
- Diagnostic tool for age-related macular degeneration
- Diagnostic tool for age-related macular degeneration
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor